Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Stock pick for 2024: The market has not spotted RELX for the AI winner it is

FTSE 100 firm RELX (REL) is ‘ahead of the game’ when it comes to integrating artificial intelligence (AI) into its business and we think this continues to be underappreciated by the market. We expect that to change in 2024 and this makes the shares a compelling investment for the year ahead.
RELX takes large datasets and analyses these for clients across a range of sectors as well as publishing scientific journals and research. The latter includes ScienceDirect - the world’s largest platform dedicated to peer reviewed primary scientific and medical research - which has proved to be resilient particularly in times of macroeconomic and geopolitical uncertainty.
The company has been investing in innovation around data analytics and AI for several years which is helping to reinforce an already strong competitive position. It is also supporting a move from a low-single-digit organic growth rate to mid-single digit growth, with the company’s progress augmented by bolt-on acquisitions.
The company has four separate divisions: risk, legal, exhibitions and scientific, technical, and medical (STM) and enjoys strong recurring revenue thanks to a subscription-based business model.
RELX observes that its products often account for less than 1% of its customers‘ total cost base but can have a significant and positive impact on the economics of the remaining 99%. In other words what RELX charges its customers is a very small proportion of their overall spend but is also really significant to how they do business which helps reinforce the stickiness of its revenue streams.
The application of generative AI is probably most advanced in the legal division where its Lexis +AI product is bringing artificial intelligence capabilities to its existing research platform. This can help lawyers digest complex legalese and conduct useful analysis.
The company’s exhibitions division is running ahead of pre-pandemic levels with a 12% increase in first half revenue with exhibitors now using a growing range of digital tools.
The stock often looks fairly expensive but if you if you’d let a similarly lofty valuation put you off a decade or so ago, for example, you’d have missed out on a total return of more than 300% in the interim or around 15% on an annualised basis.
RELX will continue to develop and incorporate content, higher value-add analytics, decision tools and generative AI across all its segments and the company is well positioned to be beneficiary of the long-term structural growth in this area.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Case study
Feature
- Return from our 2023 share picks is more than four times that of the UK market
- The best and worst emerging markets in 2023
- Can electricals leader Currys deliver some turnaround spark?
- Discover the stocks the professionals changed their minds on in 2023
- Emerging markets: China property fixes and dollar weakness
Great Ideas
- 10 stocks for 2024: our best ideas for the year ahead
- Stock pick for 2024: Adobe is one of the best ways to play AI
- Stock pick for 2024: Buy Smith & Nephew for continued recovery and re-rating potential
- Stock pick for 2024: Buy Puretech Health for lower risk access to an exciting drug portfolio
- Stock pick for 2024: MongoDB is one of the hottest software plays on AI
- Stock pick for 2024: B&M's growth ambitions and value focus make it a compelling story
- Stock pick for 2024: Hunting is attractively priced and evidence of transformation is a clear catalyst
- Stock pick for 2024: The market has not spotted RELX for the AI winner it is
- Stock pick for 2024: Just Group is so cheap and has big growth drivers behind it
- Stock pick for 2024: Hollywood Bowl is a strikingly resilient operator trading at the wrong price
- Stock pick for 2024: Take advantage of this 'generational opportunity' to buy Conduit
Investment Trusts
News
- How TSMC could set the New Year tone for tech
- Markets higher despite mixed rates messaging and what to expect from retailers
- Discover the most unloved and most-shorted UK stocks
- Costco climbs to all-time high as members clamour for cheap essentials
- A big acquisition and a slowdown in its largest market have unnerved investors in Rentokil
- UK housebuilders Taylor Wimpey and Persimmon have moved-up strongly